CRCG surged roughly +105% over the last 30 days, from about $8.05 to $16.52, as 2x daily leverage amplified a rebound in underlying Circle Internet Group (CRCL) shares. Over the trailing quarter the fund remains down about 38% , reflecting a sharp drawdown earlier in the period followed by a rapid recovery.
AXTX, a 2x leveraged ETF tracking AXT Inc. (AXTI), gained +5.33% to $7.51 during the regular session on Aug 25 versus the prior close of $7.13. The advance reflects roughly double the underlying AXTI's +3.12% gain, amplified by the fund's daily 2x leverage.
BMNU, a 2x leveraged ETF tracking Bitmine Immersion Technologies (BMNR), closed up +5.73% at $20.11 versus the prior session's $19.02 during regular market hours. The gain reflects its 2x exposure to BMNR, which rose +2.82% to $24.82 on the same day.
USO fell -4.62% to $126.10 during regular trading, sliding from the prior session's $132.21 close. The drop tracks WTI crude, which tumbled more than -3% to roughly $82 per barrel as geopolitical risk premium unwound.
SMCI is up +8.81% during the regular session, trading near $38.27 versus Friday's close of $35.17. The primary catalyst: Cisco expanded its "Secure AI Factory with NVIDIA" to include Supermicro's high-density liquid- and air-cooled servers.
AMIX surged +46.74% to $7.88, up from the prior session's close of $5.37, with the gain extending through premarket and regular trading hours. The move followed the company's announcement of a $4.9 million warrant inducement agreement, priced at a premium under Nasdaq rules.
Sionna Therapeutics (SION) shares have fallen roughly 86% over the last 30 days, driven almost entirely by a single-day collapse following disappointing clinical trial data. The decline followed the failure of SION-719, the company's lead cystic fibrosis candidate, in a Phase 2a proof-of-concept trial announced in August 2026.
YARW shares have gained roughly 55% over the last 30 days, climbing from about $25.45 to near $39.50. The advance followed Yarrow Bioscience's Nasdaq debut after completing its merger with VYNE Therapeutics in late July 2026.
TNMG jumped +37.5% during regular trading to roughly $0.55, versus a $0.40 prior-session close. The catalyst was news that the Nasdaq Hearings Panel granted the company continued listing on the Nasdaq Capital Market, removing the immediate delisting overhang.
DAIC is up +78.61%, trading near $3.09 in the regular session after closing Monday at $1.73. The move extends Monday's +306% surge, driven by momentum and a short-squeeze-style continuation in a heavily shorted microcap.
AIXI surged roughly +187% to about $1.32 intraday versus a prior close of $0.46, extending an earlier premarket gain of nearly +90%. The advance occurred during regular trading hours, with premarket follow-through, on sharply elevated volume.
COKE shares recently traded near $192, leaving roughly a 30% gap to the widely discussed $250 price level. $250 would mark a new all-time high, above the stock's previous record close around $219.65 set in March 2026.
FBDT closed down -48.62% (-$1.94) to $2.05 from a prior close of $3.99, during regular Nasdaq session trading. The decline occurred in market hours, not premarket or after-hours.
SWVL surged roughly +62.4% during regular market hours, jumping from a prior close of $1.49 to about $2.42 intraday on heavy volume. The primary catalyst was the announcement of a $13 million PIPE led by Coefficient LP, backed by the Sawiris family, which will become the company's largest institutional shareholder.
GRRR is down -12.26% to about $13.89 during Tuesday's regular session, after closing at $15.83 on Monday. The selloff follows H1 2026 results: revenue nearly doubled (+99% to $78.4M), but an adjusted loss of $0.58/share badly missed estimates and reversed a year-ago profit.
SLQT is down -28.21% (about -$0.22) to roughly $0.56, extending a premarket slide into the regular session. Catalyst: fiscal Q4 2026 results missed on both lines — a $0.19/share loss versus a -$0.15 consensus and revenue of $321.7M versus ~$345.3M expected.
DKS shares plunged about -19.51% to roughly $144.34 in the latest session, down from Monday's close of $179.33, with the decline starting in premarket trading. The selloff followed a Q2 miss: adjusted EPS of $3.53 versus a $3.76-$3.78 consensus, and revenue of $5.59B below the ~$5.64B estimate.
DKS shares plunged about -19.51% to roughly $144.34 in the latest session, down from Monday's close of $179.33, with the decline starting in premarket trading. The selloff followed a Q2 miss: adjusted EPS of $3.53 versus a $3.76-$3.78 consensus, and revenue of $5.59B below the ~$5.64B estimate.
Selected price target: $13 per share, roughly 47% above Wendy's recent trading range and aligned with the highest Wall Street price objective. Strongest bullish factors: Activist investor interest from Trian Fund Management, an aggressive turnaround and international expansion plan, and a deeply discounted valuation with a high dividend yield.
Macro drivers such as interest rate paths and inflation trends will shape capital spending in semiconductor manufacturing and design. The semiconductor sector outlook remains tied to artificial intelligence adoption, data center expansion, and automotive electrification over the medium term.